Journal of Immunology Research / 2012 / Article / Tab 1

Review Article

Rituximab-Based Treatment, HCV Replication, and Hepatic Flares

Table 1

Studies on rituximab-based chemotherapy that investigated both HCV reactivation and hepatic flares.

   Coppola et al., 2012 [40]Ennishi et al., 2010 [36]Marignani et al., 2011 [39]Pitini et al., 2010 [38]Tsutsumi et al., 2009 [37]

Type of studyObservational prospectiveMulticentre retrospectiveObservational retrospectiveObservational prospectiveObservational prospective
DiseaseLNH, CLL LNH (DLBCL)LNHLNH (DLBCL, FL)LNH (DLBCL)
Number of cases8343104
TreatmentR-CHOP in 5R- and P-basedR-CHOPRCHOPR-CHOP in 1
R-FC in 1chemotherapyR-CHO in 2
CP and then R-FCR-THP-CO in 1
in 1
FC in 1
With HCV reactivation, number of cases:7342104
 During CT7340104
 After CT00200
With hepatic flare, number of cases: 7 The available datum (27%) refers to flares observed in 131 patients, of whom only 34 were followed up for HCV RNA 2 10 3
 During CT70103
 After CT0200

NHL: non-Hodgkin lymphoma; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; CLL: chronic lymphocytic leukaemia; R-CHO: rituximab, cyclophosphamide, doxorubicin, vincristine; RFC: rituximab, fludarabine, and cyclophosphamide; CP: cyclophosphamide, prednisone; FC: fludarabine and cyclophosphamide; R-THPCOP: rituximab, pirarubicin (tetrahydropyranyl-adriamicin [TPH] ) cyclophosphamid, vincristine without prednisone.